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Okadaic acid strongly increases gene transcription, mRNA and protein 
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The specific phosphalase inhibitor, okadaic acid, increases the level ofmRNA for the receptor (or urokinase-type lasminogen activator (u-PAR) 
in 8 out of 13 human cell lines. The strongest increase (90.fold) was observed in AS49 lung carcinoma cells, in which it was parlly traced back 
to an increased transcription of the u-PAR gene. There was a parallel but less pronounced increase in the u-PAR protein level. These findings 
indicate that u-PAR gene transcription is regulated by one or more factors that arc constitutively phosphorylated and are dephosphorylated by 
okadaic acid-sensitive phosphatases, A lack of additivity of u-PAR induction by okadaic acid and by the protein kinase C activator, PMA, in the 
A549 cells suggests that the regulatory factors affected by okadaic acid arc phasphorylated byprotein kinaw C. 
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1. INTRODUCTION 
Generation of the broad-spectrum protease plasmin 
by urokinase-type plasminogen activator (uPA) is in- 
volved in degradation of extracellular matrix proteins 
in a variety of biological processes requiring tissue 
destruction or cell migration. The activity of uPA is 
regulated by two specific and fast-acting plasminogen 
activator inhibitors, PAI- and PAZ-2, and by a specific 
cell-surface uPA receptor (u-PAR) [l-3]. 
cytokines [1,14--161. Recently we found that the tumor 
promoter PMA and transforming rowth factor-p1 
(TGF-pl) in certain cell types increase the u-PAR 
mRNA level and gene transcription [17,18]. We now 
report that okadaic acid, an inhibitor of serine/ 
threonine phosphatases [ 191 increases the u-PAR 
mRNA level in 8 out of 13 human cell lines. The 
strongest effect is seen in AS49 lung carcinoma cells. In 
this cell line, okadaic acid also induces u-PAR gene 
transcription and increases the level of receptor protein. 
u-PAR was first detected on monocytes and mo- 
nocyte-like cells by a specific, high-affinity binding of 
uPA 143 and its zymogen pro-uPA [5]. It has since been 
observed on a variety of cultured cell lines of neoplastic 
and non-neoplastic origin [&93. We recently purified 
and characterized human u-PAR [9,10] and cloned a 
full-length cDNA coding for this receptor [I 11. u-PAR 
is an A4r 55-66,000, single-chain, highly glycosylated 
protein attached to the plasma membrane by a gly- 
cosyl-phosphatidylinositol lipid anchor [ 121. It consists 
of three homologous repeats of which the N-terminal 
binds uPA [ 131. 
2. MATERIALS AND METHODS 
2. I. Murrrials 
Okadaic acid was obtained from Boehrlnger (Mannheim, 
Germany). All other materials were purchased as dcscribcd 
[12,13,17,18,20]. 
2.2. Cell chrr 
The synthesis of uPA, its inhibitors and u-PAR is 
controlled by a variety of hormones, growth factors and 
Abbrcviurions: uPA, urokinase-type plasminogcn activator; u-PAR, 
uPA receptor; ATF. NH,-terminal fragment (l-135) of uPA; PAI-I , 
plasminogcn activalor inhibitor type-l; PAl-2. plasminogen activator 
inhibitor type-a; PMA. phorbol Ilmyristate If-acetate; TGF-,&, 
transforming rowth factor-p type 1; EGF, epidermal growth factor; 
DSS, disuccinimidyl subcrate; SDS-PAGE, sodium dodecyl sulfate 
polyacrylamide gel electrophoresis, 
The human lung carcinoma cell lint AS49 (American Type Culture 
Collection (ATCZ) CCL I@), the embryonal lung fibroblast cell lines 
WI-38 (ATCC CCL 75) and He1299 (ATCC CCL l37), the larynx 
cpidermal carcinoma cell line HEp-2 (ATCC CCL 23), the epithcloid 
cervix carcinoma HeLa (ATCC CCL 2), and the human rhabdomyo- 
sarcoma cell lint RD (ATCC CCL 136) were obtained from Flow 
laboratories, Irvine, UK. The promyeloid leukemic ell line HtC60 
(ATCC CCL 240) and the chronic myelogcneoua leukemic ell line 
K-562 (ATCC CCL 243) were obtained from ATCC. Rockvillc Pike, 
MD, USA. The librosarcama cell lines l-IT-1080 (ATCC CCL 121) 
and 8387 were obtained from Dr. A. Vaheri. University of Helsinki. 
Finland. The monocyte-like cell line U937 (ATCC CRL 1593) was 
obtained from Dr. A. Fattorossi. Rome, Italy). The melanoma cell 
lines Bowes and %lIAI were obtained from Dr. C. Kluft, Leiden, The 
Netherlands and Dr. J. Zeuthen. Copenhagen. Denmark, respectively. 
Corrcsporrdcncc address: L.R. Lund, Finsen Laboratory, Rigshospi- 
talet, Strandboulevardcn 49, DK-2100 Copenhagen RI, Denmark, 
Fax: (45) 3138 S450. 
Approximately I@ trypsiniaed cells were seeded in I5 cm Petri 
dishes and grown to coniiucncy in Dui’becco’s modified Eagk’s 
medium supplemented with 10% fetal calf serum as described [l8], 
with the exception ofthe suspension growing U937, HL-60 and K-S62 
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Fig. 1. Northern blot analysis of effect of okadaic acid on u-PAR mRNA level in human cell lines. The indicated cell lines were incubated for 6 
h with (+) or without (-) 100 nM okadaic acid and harvested. Their total RNA was isolated. For Northern blot analysis, 30.~~ of the total RNA 
were electrophoresed in 1.5% agarosc gels under denaturing conditions and blotted onto a nitrocellulose filter. The membrane was hybridized with 
a randomly primed Wlabcled u-PAR cDNA probe (A), and as a control, after stripping. it was rehybridixcd with a GAPDH cDNA probe (D). 
The position of the ribosomal RNAs arc indicated to the left and the mRNA bands to the right. Elhidium bromide staining of the agarose gel 
and the blot showed an approximately equal amount of intact RNA in all lanes (data not shown). in this experiment a prolonged exposure of the 
blot was performed (2 days) in order to obtain detectable u-PAR mRNA signals in the different cell lines. 
cell lines which were cultured at a density of approximately 0.5 x IO6 
cells/ml in RPMI-1640 medium supplemented with 10% fetal calf 
serum. Fetal calf serum was also present in the medium for these latter 
cell lines throughout the cxpriments, while all the adherent cell lines 
were kept under serum-free conditions during the experiment and 
through a 48-72 h preaincubation period. Cells wcrc harvested as 
described [IS]. 
2.3, Vwiolrs procedrrres 
Total RNA was isolated by acid guanidinium thiocyanate-phenol- 
chloroform extraction and analyzed by Northern blotting [I 71. Chcmi- 
cul cross-linking of u-PAR to ‘251-labelcd ATF was done on total 
detergent lysate of the cells [IO]. Nuclear transcription assays were 
performed as described [17]. 
3. RESULTS 
3.1. CeIi-speciJic expression und regulation of u-PAR 
ntRNA level by okadaic mid in hunzan cell hes 
The responsiveness of the u-PAR mRNA level to 
okadaic acid was studied in 13 human cell lines by 
Northern blot analysis with a full-length cDNA probe 
for u-PAR [l 11. Fig. 1 shows that the basal level of 
u-PAR mRNA varies trongly between the different cell 
lines. The treatment with okadaic acid resulted in an 
increased level of u-FAR mRNA in U937, WI-38, He1 
299, 8387, A549, HeLa, HEp-2 and MIA1 cells. No 
effect of okadaic acid was observed in the remaining cell 
lines. 
The strongest response to okadaic acid was observed 
with the A549 cells which we chose for a more detailed 
study of the okadaic acid regulation of u-PAR expres- 
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sion. Fig. 2 shows the accumulation of u-PAR mRNA 
in A549 cells after 6 h incubation with the indicated 
concentrations of okadaic acid. There was no effect on 
the GAPDH mRNA level (Fig. 2B), which therefore 
was used for normalization. A maximal -90-fold in- 
crease in the u-PAR mRNA level is reached at 100 nM 
of okadaic acid and a half-maximal effect at =20 nM. 
At an okadaic acid concentration of 200 nM there was 
a pronounced toxic effect on the cells. Concentrations 
higher than 100 nM were therefore not tested in the 
subsequent experiments. 
In order to study the kinetics of the induction, the 
A549 cells were treated with 50 nM okadaic acid for 
different ime periods and analyzed by Northern blot- 
ting (Fig. 3). Densitometric scanning of the autora- 
diograms howed that the u-PAR mRNA level was sig- 
nificantly increased after 1.5 h, reached a maximal 90- 
fold increase after 16 h of okadaic acid treatment and 
then remained almost constant for up to 24 h. 
3.2. Effect of okadaic acid on u-PAR gene transcription 
The effect of okadaic acid on transcription of the 
u-PAR gene was measured with a nuclear transcription 
(run-on) assay. Nuclei were isolated from A549 cells 
cultured for G h in the presence or absence of 50 nM 
okadaic acid, followed by incubation with 3’P-labell~ed 
uridine triphosphate for 40 min. Fig. 3C shows autor - 
diograms of radiolabelled RNA from these nuclei hi - 
bridized to filters containing the indicated cDN , 
probes. Densitometric scannings of the autoradiograms 
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Fig. 2. Dose-dependency of okadaic acid induction of u-PAR mRNA 
in AS49 cells. A549 cells were cultured for 6 h with the indicated 
concentrations of okadaic acid, harvested and analyzed by Northern 
blotting as described in the @end to Fig. I. Hybridizations with the 
u-PAR cDNA probe is shown in insert A, and re-hybridization ofthe 
stripped blot with a GAPDH EDNA probe in insert B. The numbers 
in the insert indicate non-treated cells (lane I), and cells treated with 
okadaic acid in a concentration of 0.01 nM (lane 2). 0. I nM (lane 3), 
1.0 nM (lane 4), 10 nM (lane S), 50 nM (lane 6). 100 nM (lane 7) and 
200 nM (lane B), The relative amount of u-PAR mRNA at each 
concentration was estimated by scanning of the Northern membranes 
hybridized with the u-PAR probe after normalization against the 
corresponding relative amounts of GAPDH mRNA. The u-PAR 
mRNA level in the non-treated cells has been scl equal to 1 and at each 
concentration is expressed as fold induction. 
showed an &fold increase in u-PAR gene transcription 
while ~110 effect was detected on the level of GAPDH 
gere transcription. 
3.3. Effect of okadctic acid on u-PAR proteivr levei 
Induction of the u-PAR protein was studied with a 
sensitive and specific hemical cross-linking technique, 
in which u-PAR is bound to the amino terminal frag- 
ment (ATF) of the u-PA molecule [ 101. After treatment 
of the cells with 50 nM okadaic acid for different ime 
periods, Trlton X-l 14 extracts were cross-linked to “% 
labeled ATF and analyzed by SDS-PAGE and auto- 
radiography. A weak but visible signal of cross-linked 
lzSI-ATF was seen in non-treated A549 cells (Fig. 4). 
After 3 h of incubation in the presence of okadaic acid, 
there was an increase in the intensity of the signal, which 
continued up to 24 h of incubaticn, after which a small 
decrease in binding capacity was observed. After the 
autoradiography the areas of the gel corresponding to 
u-PAlUATF complexes were excised and counted in a 
gamma-counter. This analysis indicated a maximal 1% 
fold increase in radioactivity after 24 h of okadaic acid 
treatment (data not shown). 
3.4. Effect of okadaic acid in combinorion with PMA or 
TGF#I on the u-PAR mRNA level 
At least wo signaling pathways are known to involve 
factors that are dephosphorylated by okadaic acid- 
sensitive phosphatases, the protein kinase-C pathway 
and the CAMP-dependent protein kinase pathways [22- 
26]. Previously, we have found that the protein kinase 
C activator, PMA, increases the U-PAR mRNA level in 
A549 cells, while CAMP is without any effect ([18], un- 
published result). In order to evaluate whether the 
okadaic acid effect on the u-PAR mRNA level was 
mediated by a factor involved in the protein kinase C 
pathway, we examined the combined effect of okadaic 
acid and PMA in doses that for each of the compounds 
had a maximal effect on the u-PAR _mRNA level, In a 
separate xperiment he maximally effective dose of 
PMA was found to be 150 nM with a 6 h incubation 
period (results not shown). As seen in Fig. 5 there was 
no additive effect when 100 nM okadaic acid and 150 
nM PMA was used in combination. This result would 
be expected if phosphorylation of the same factor is 
involved in the action of the two compounds. 
The u-PAR mRNA level is also increased by TGF-/I1 
[18], The combination of okadaic acid and TGF-11 re- 
sulted in an additive (or even synergistic) effect on the 
u-PAR mRNA level (Fig. 5). This finding is in agree- 
ment with the TGF$l-dependent signaling pathway 
not being supposed generally to involve factors in- 
fluenced by okadaic acid [27], 
4. DISCUSSION 
In 8 out of 13 human cell lines okadaic acid caused 
an increase in the level of u-PAR mRNA while no effect 
on this level was observed in the remaining 5 cell lines. 
The okadaic acid-responsive c ll lines were found both 
among those of epithelial (AS49, HEp-2, HeLa and 
MIAI), mesenchymal (WI-38, Mel 299 and 8387) and 
leukemic (U937) origin. The strongest response was 
seen in A549 cells, lung carcinoma cells, in which the 
effect was both time- and dose-dependent, the maximal 
induction observed being approximately 90-fold. This 
increase was partly traced back to an increased 
transcription of the u-PAR gene. In the A549 cells there 
was also an increase in u-PAR protein of maximally 
1 S-fold which was fully accounted for by the increase in 
the mRNA level. 
Okadaic acid is an inhibitor of the serinejthreonine- 
specific protein phosphatases, 1 and 2A [19,26]. The 
present findings indicate that one or more factors which 
regulates u-PAR gene expression in the A549 cells (and 
presumably the other 7 cell lines in which okadaic acid 
increases the u-PAR mRNA level) are continually being 
179 
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Fig, 3. Northern blot and nuclear transcription analysis of cells treated with okadaic acid for different ime periods. Experimental conditions were 
as described in the legend to Fig. 2, except hat thecells were treated with 50 nM okadaic acid for the indicated time periods. The membranes were 
hybridized with a randomly primed p’P]-labeled u-PAR cDNA probe (A), and, after stripping, re-hybridized with a GAPDH cDNA probe (B). 
The normalized rclarive amounts of u-PAR mRNA as determined by densitometric s anning are indicated in (D). In (C) the transcriptional ctivity 
of the human u-PAR gene, following stimulation by okadaic acid, was dctc.z,ilined by hybridizing nitrocellulose membranes, containing immobilized 
cDNa probes as indicated, with [‘zP]-labeled RNA, prepared from nudei isolated from control cells or cells treated with 50 nM okadaic acid for 
6 h. The membranes were exposed for 7 days. pUCl8 indicates H conrrol vector cDNA. 
phosphorylated and dephosphorylated, the dephos- 
phorylation being catalyzed by okadaic acid-sensitive 
phosphatases. Okadaic acid will then change the equi- 
librium towards the phosphorylated form of this factor, 
which again directly or indirectly enhances u-PAR 
transcription. 
The findings that okadaic acid and PMA each 
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Fig. 4. Time-course of okadaic acid induction of u-PAR protein as 
detected by chemical cross-linking to ‘?‘I-ATF. Non-treated cells (lane 
3) and cells treated with 50 nM okadaic acid for 3 h (lane 3), G h (Itine 
4), 12 h (lane T), 24 h (lane G) and 48 h (lane 7) were acid-treated to 
remove endogenous uPA. and detergent cxtrz:s were prepared as 
described in Materials and Methods. Non-diluted extracts and a 
buffer control sample (lane 1) were incubated with ‘?%ATF, cross- 
linked with DSS and run in a 616% SDS-PAGE gradient gel under 
non-reducing conditions followed by autoradiogmphy. Electrophore- 
tic mobilities of molecular weight standard proteins are indicated on 
the left. The extracts were prepared from cells used in the experiments 
described in Fig. 3. 
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strongly enhance the u-PAR mRNA level in A549 cells, 
and that the combination of the two compounds in 
maximally effective doses do not have any additive 
effect, suggest hat the regulating factor(s), which in 
these cells is affected by okadaic acid, is the same as the 
factor(s) phosphorylated by protein kinase C after 
PMA stimulation. An alternative xplanation for the 
lack of additive effect of the two compounds would be 
that each of them, by independent mechanisms, are able 
tc induce the maximally obtainable transcription rate. 
This explanation is, however, less likely, because acom- 
bination of okadaic acid and TGF-@ caused a u-PAR 
mRNA level which was considerably higher than that 
obtained with okadaic acid and PMA. 
Binding of uPA to its receptor enhances and localizes 
plasmin formation [2,3] and both uPA and u-PAR 
appear to play important roles in tissue destruction in 
normal and pathological conditions, including cancer 
invasion [l-3,20,21]. In some types of cancer (such as 
colon adenocarcinomas and squamous skin car- 
cinomas) u-PAR is expressed in cancer cells located at 
the tumoral-stromal interface of invasive foci but not 
in cancer cells located in other areas of the tumors ([21], 
C. Pyke, persona1 communication). These findings indi- 
cate that the u-PAR expression in these cancer cells is 
regulated by factors in the microenvironment. We have 
previously shown that different hormones, growth 
factors and cytokines, such as TGF-,&I, EGF and dexa- 
methasone, regulate u-PAR expression in a cell specific 
manner (17,181, unpublished observations). A clarifica- 
tion of the signal pathways involved in this regulation 
Volume 298, number 2,3 FEBS LETTERS February 1992 
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Fig. 5. Northern blot analysis ofthccffect of okadaicacid in combina- 
tion with PMA or TGF-/3I on the u-PAR mRNA level in A549 cells. 
Total RNA was isolated from cells incubated for 6 h with noadditions 
(luncs I and S), wilh 100 nM okadaic acid (lanes 3 and 7), 5 nS/ml 
TGF-pl (lane 2), a combination of 5 ng/ml TGF$I and 100 nM 
okadaic acid (lane 4), I50 nM PMA (lane 6) and a combination of I50 
nM PMA and 100 nM okadaic acid (lane 8). Northern blot analysis 
was performed as described in the legend to Fig. I. with a u-PAR 
la346678 
cDNA probe (A) and a GAPDH probe (B). 
is important for an understanding of the mechanism of 
the preferential expression of u-PAR in some cancer 
cells during invasion. The present study indicates that 
the signal transduction in many cells of neoplastic origin 
involves threoninekerine phosphorylation of one or 
more factors that induce u-PAR gene transcription. A
further identification of these factors would be faci- 
litated by the isolation and characterization of the u- 
PAR gene. 
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